Esperite, sustainable strategy
Esperite has positioned its goal towards contribution to health improvement. Regenerative and predictive medicine are the bedrocks of lifespan extension.
Longevity and healthy aging are the most exciting studies and subjects for promising researches in the field of genetics and regeneration of biological functionalities.
Lifespan is since the first signs of human consciences and recording of scientific facts, one of the main concerns of our form of humanity.
The dramatic increase of average life expectancy over the last decades or century is the result of a sophisticated balance of genetic and environmental, non genetic, factors. Basic metabolisms, under the control of our inherited genes are modulated by our lifestyle.
The discovery of how genetic basis modulates longevity will definitely contribute on specifically adapting or correcting lifestyle in order to reach a healthier longevity and
extend health span.
Regenerative medicine was first stated in 1992. Short after, in 2000, CryoSave, now in Esperite, dedicated its activity developing the potential of Cord Blood and hematopoietic stem cells. Esperite introduced one of the first method for processing the mesenchymal Stem Cells isolated from the Wharton’s Jelly studied in early stage clinical trials for cardiovascular repairs and immunological modulations
Maintaining our leadership position
We proudly defend our position of leader within our industry. We are the largest private Stem Cell company in Europe. We are the largest autologous and allogeneic private Stem Cell bank, dedicated to the individuals, families and community. To maintain our leadership position, we raise our commitment to the next level, we integrate excellence in quality, efficient research, dedicated performant team. Our stakeholders, customers, patients are our focus point.
Engaging Diversification and sustainability
Esperite stands on three pillars, well balancing synergy and mutual contribution. Our management is engaging every level of our organisation in a total commitment to impose our values of excellence, quality, performance and sustainability to our conduct of business. We have engaged an ambitious plan of normalisation and accreditation of all our different business units and divisions. Sustainability is now at the heart of our global system.
Investing in Innovation and translation
Genoma genetic tests are contributing to this precise, personalized approach to patient care for both prevention and treatment by empowering doctors and clients with relevant early actionable genetic information.
Regenerative medicine, personalized medicine by definition, is becoming more important in the aging population and is based on the principle of using stem cells to rebuild tissue damaged by injury or disease. Stem cells are the building blocks of life.
The Cell Factory controls the entire production process of stem cells derived exosomes from procurements, through processing to production and filling of the final product.
Esperite is investing in translation of sophisticated technologies to immediate clinical applications.
Investing in Caring and Nurturing our Customers
We are dedicated to maintaining the strongest link with our customers. We maintain the highest quality for the satisfaction of our customers and patients. Our products and services are elaborated with the most stringent criteria in mind. The right choice for the best technology, available at the most affordable price and always compliant with the local and international regulation. We monitor the impact of that consumer concern and forwardthinking code of conduct has on product efficiency.
We build channels of distribution and have brought our partners to the appropriate level. We train and educate our teams under a continuous education program. We are establishing longevity in our network and bringing robustness in our services. We build trusted relationships with our consumers. We build sustainability
Investing in our future
We are a team of people with a strong dedication to sustainability. We are proud of our achievement and thank our shareholders for their confidence and our recent investor for its recognition of our effort and its involvement. Our commitment, at every level of the company and in every of the 30 countries where we operate, will lead us successful towards a bright profitable future.
Frederic A. Amar